A perspective on the contribution of animal models to the pharmacological treatment of posttraumatic stress disorder

Abstract

Objectives:

Posttraumatic stress disorder (PTSD) is a prevalent, chronic, disabling disorder that may develop following exposure to a traumatic event. This review summarizes currently used animal models of PTSD and their potential role in the development of better therapeutics. Heterogeneity is one of the main characteristics of PTSD with the consequence that many pharmacological approaches are used to relieve symptoms of PTSD. To address the translational properties of the animal models, we discuss the types of stressors used, the rodent correlates of human PTSD (DSM-5) symptoms, and the efficacy of approved, recommended and off-label drugs used to treat PTSD in ‘PTSD-animals’.

Conclusions:

Currently available animal models reproduce most PTSD symptoms and are validated by existing therapeutics. However, novel therapeutics are needed for this disorder as not one drug alleviates all symptoms and many have side effects that lead to non-compliance among PTSD patients. The true translational power of animal models of PTSD will only be demonstrated when new therapeutics acting through novel mechanisms become available for clinical practice.

Keywords

posttraumatic stress disorder animal models therapeutics

Get full access to this article

View all access options for this article.

References

Jeffreys

. Clinicians guide to medications for PTSD, http://www.ptsd.va.gov/professional/treatment/overview/clinicians-guide-to-medications-for-ptsd.asp (2017, accessed 1 July 2017).

Brady

Killeen

Brewerton

. Comorbidity of psychiatric disorders and posttraumatic stress disorder. J Clin Psychiatry 2000; 61: 22–32.

Kessler

Sonnega

Bromet

. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52: 1048–1060.

Hoskins

Pearce

Bethell

Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Br J Psychiatry 2015; 206: 93–100.

Raskind

Peskind

Hoff

DJ.

A parallel group placebo controlled study of Prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007; 61: 928–934.

Borghans

Homberg

RH.

Animal models for post-traumatic stress disorder: An overview of what is used in research. World J Psychiatry 2015; 5: 387–396.

Daskalakis

Yehuda

Diamond

DM.

Animal models in translational studies of PTSD. Psychoneuroendocrinology 2013; 38: 1895–1911.

Cohen

Matar

MA.

Animal models of post-traumatic stress disorder. Curr Protoc Neurosci 2013; Unit 9.45.1–9.45.18.

Golden

Covington

3rd Berton

. A standardized protocol for repeated social defeat stress in mice. Nat Protoc 2011; 6: 1183–1191.

10.

Blanco

. Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: Results from National Epidemiological Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2013; 132: 630–638.

11.

Cohen

Zohar

Gidron

Blunted HPA axis response to stress influences susceptibility to posttraumatic stress response in rats. Biol Psychiatry 2006; 59: 1208–1218.

12.

Goswami

Rodríguez-Sierra

Cascardi

. Animal models of post-traumatic stress disorder: Face validity. Front Neurosci 2013; 7: 1–14.

13.

Kao

. Fluoxetine treatment prevents the inflammatory response in a mouse model of posttraumatic stress disorder. J Psychiatr Res 2016; 76: 74–83.

14.

Matar

Cohen

Kaplan

. The effect of early poststressor intervention with sertraline on behavioral responses in an animal model of post-traumatic stress disorder. Neuropsychopharmacology 2006; 31: 2610–2618.

15.

Miao

Y-L

Guo

W-Z

Shi

W-Z

. Midazolam ameliorates the behavior deficits of a rat posttraumatic stress disorder model through dual 18 kDa translocator protein and central benzodiazepine receptor and neurosteroidogenesis. PloS One 2014; 9: 1–8.

16.

Takahashi

Morinobu

Iwamoto

. Effect of paroxetine on enhanced contextual fear induced by single prolonged stress in rats. Psychopharmacology (Berl) 2006; 189: 165–173.

17.

Perrine

Eagle

George

. Multimodal stress exposure induces PTSD-like characteristics in a mouse model of single prolonged stress. Behav Brain Res 2016; 303: 228–237.

18.

Wang

. Conditioned fear stress combined with single-prolonged stress: A new PTSD mouse model. Neurosci Res 2012; 73: 142–152.

19.

Yang

Shi

Zhu

WL.

Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear. Behav Brain Res 2012; 230: 268–273.

20.

Laitman

Gajewski

Mann

. The α1 adrenoceptor antagonist prazosin enhances sleep continuity in fear-conditioned Wistar-Kyoto rats. Progr Neuropsychopharmacol Biol Psychiatry 2014; 3: 7–15.

21.

Wilson

McLaughlin

Ebenezer

. Differential effects of sertraline in a predator exposure animal model of post-traumatic stress disorder. Front Behav Neurosci 2014; 256: 1–11.

22.

Zoladz

Diamond

DM.

Current status on behavioral and biological markers of PTSD: A search for clarity in a conflicting literature. Neurosci Biobehav Rev 2013; 37: 860–895.

23.

Kao

. Fluoxetine treatment rescues energy metabolism pathway alterations in a posttraumatic stress disorder mouse model. Mol Neuropsychiatry 2016; 2: 46–59.

24.

Braun

Greenberg

Dasberg

. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236–238.

25.

Davidson

JRT

Brady

Mellman

. The efficacy and tolerability of tiagabine in adult patients with posttraumatic stress disorder. J Clin Psychopharmacol 2007; 27: 85–88.

26.

Davis

Davidson

JRT

Ward

. Divalproex in the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008; 28: 84–88.

27.

Hart

Panayi

Harris

. Benzodiazepine treatment can impair or spare extinction, depending on when it is given. Behav Res Ther 2014; 56: 22–29.

28.

Sotres-Bayon

Cain

Brain

LJE

. Mechanisms of fear extinction: Historical perspectives on the contribution of prefrontal cortex. Biol Psychiatry 2006; 60: 329–336.

29.

Kokras

Dalla

Sex differences in animal models of psychiatric disorders. Br J Pharmacol 2014; 171: 4595–4619.

30.

Shansky

RM.

Sex differences in PTSD resilience and susceptibility: Challenges for animal models of fear learning. Neurobiol Stress 2015; 1: 60–65.

31.

Nedelcovych

Gould

Zhan

A rodent model of traumatic stress induces lasting sleep and quantitative electroencephalographic disturbances. ACS Chem Neurosci 2015; 6 485–493.

32.

Vanderheyden

. Sleep alterations following exposure to stress predict fear-associated memory impairments in a rodent model of PTSD. Exp Brain Res 2015; 233: 2335–2346.

33.

Cui

Zhang

XQ.

Different neural circuitry is involved in physiological and psychological stress-induced PTSD-like ‘nightmares’ in rats. Sci Rep 2015; 5: 1–14.

34.

US Department of Veterans Affairs. PTSD and substance abuse in veterans, http://www.ptsd.va.gov/public/problems/ptsd_substance_abuse_veterans.asp (2015, accessed 1 July 2017).

35.

Logrip

Zorrilla

Koob

GF.

Stress modulation of drug self-administration: Implications for addiction comorbidity with post-traumatic stress disorder. Neuropharmacology 2012; 62: 552–564.

36.

Klaassens

Giltay

Cuijpers

. Adulthood trauma and HPA-axis functioning in healthy subjects and PTSD patients: A meta-analysis. Psychoneuroendocrinology 2012; 37: 317–331.

37.

Almli

Fani

Smith

. Genetic approaches to understanding post-traumatic stress disorder. Int J Neuropsychopharmacol 2014; 17: 355–370.

38.

Logue

. The Psychiatric Genomics Consortium Posttraumatic Stress Disorder Workgroup: Posttraumatic stress disorder enters the age of large-scale genomic collaboration. Neuropsychopharmacology 2015; 40: 2287–2297.